Cargando…
Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121106/ https://www.ncbi.nlm.nih.gov/pubmed/35589333 http://dx.doi.org/10.1136/rmdopen-2022-002323 |
| _version_ | 1784711085208633344 |
|---|---|
| author | Fagni, Filippo Schmidt, Katja Bohr, Daniela Valor-Méndez, Larissa Hartmann, Fabian Tascilar, Koray Manger, Karin Manger, Bernhard Kleyer, Arnd Simon, David Schett, Georg Harrer, Thomas |
| author_facet | Fagni, Filippo Schmidt, Katja Bohr, Daniela Valor-Méndez, Larissa Hartmann, Fabian Tascilar, Koray Manger, Karin Manger, Bernhard Kleyer, Arnd Simon, David Schett, Georg Harrer, Thomas |
| author_sort | Fagni, Filippo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9121106 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91211062022-05-20 Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination Fagni, Filippo Schmidt, Katja Bohr, Daniela Valor-Méndez, Larissa Hartmann, Fabian Tascilar, Koray Manger, Karin Manger, Bernhard Kleyer, Arnd Simon, David Schett, Georg Harrer, Thomas RMD Open Letter BMJ Publishing Group 2022-05-18 /pmc/articles/PMC9121106/ /pubmed/35589333 http://dx.doi.org/10.1136/rmdopen-2022-002323 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Fagni, Filippo Schmidt, Katja Bohr, Daniela Valor-Méndez, Larissa Hartmann, Fabian Tascilar, Koray Manger, Karin Manger, Bernhard Kleyer, Arnd Simon, David Schett, Georg Harrer, Thomas Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_full | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_fullStr | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_full_unstemmed | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_short | Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| title_sort | effects of casirivimab/imdevimab on systemic and mucosal immunity against sars-cov-2 in b-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121106/ https://www.ncbi.nlm.nih.gov/pubmed/35589333 http://dx.doi.org/10.1136/rmdopen-2022-002323 |
| work_keys_str_mv | AT fagnifilippo effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT schmidtkatja effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT bohrdaniela effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT valormendezlarissa effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT hartmannfabian effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT tascilarkoray effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT mangerkarin effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT mangerbernhard effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT kleyerarnd effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT simondavid effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT schettgeorg effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination AT harrerthomas effectsofcasirivimabimdevimabonsystemicandmucosalimmunityagainstsarscov2inbcelldepletedpatientswithautoimmunerheumaticdiseasesrefractorytovaccination |